14-3-3 σ and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

被引：0
|
作者：
Reguart, N.
Porta, R.
Provencio, M.
Cardenal, F.
Cuello, M.
Ramirez, J. L.
Mayo, C.
Lianes, P.
Taron, M.
Rosell, R.
机构：
[1] Hosp Badalona Germans Trias & Pujol, ICO, Badalona, Spain
[2] Hosp Josep Trueta, ICO, Girona, Spain
[3] Clin Puerta del Hierro, Madrid, Spain
[4] Hosp Duran & Reynals, ICO, Barcelona, Spain
[5] Hosp Mataro, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7600
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Frequency of EGFR Mutations in Greek Non-Small-Cell Lung Cancer (NSCLC) Patients
    Nasioulas, G.
    Efstathiadou, C.
    Murray, S.
    Dahabreh, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S635 - S635
  • [22] Frequency of EGFR mutations in Greek non-small-cell lung cancer (NSCLC) patients
    Murray, Samuel
    Papadopoulou, Eirini
    Nasioulas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
  • [24] Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
    Rosell, Rafael
    Angel Molina, Miguel
    Costa, Carlota
    Simonetti, Sara
    Gimenez-Capitan, Ana
    Bertran-Alamillo, Jordi
    Mayo, Clara
    Moran, Teresa
    Mendez, Pedro
    Cardenal, Felipe
    Isla, Dolores
    Provencio, Mariano
    Cobo, Manuel
    Insa, Amelia
    Garcia-Campelo, Rosario
    Reguart, Noemi
    Majem, Margarita
    Viteri, Santiago
    Carcereny, Enric
    Porta, Ruth
    Massuti, Bartomeu
    Queralt, Cristina
    de Aguirre, Itziar
    Miguel Sanchez, Jose
    Sanchez-Ronco, Maria
    Luis Mate, Jose
    Ariza, Aurelio
    Benlloch, Susana
    Javier Sanchez, Jose
    Bivona, Trever G.
    Sawyers, Charles L.
    Taron, Miquel
    CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1160 - 1168
  • [25] Effect of first-line treatment and CHFR and 14-3-3σ methylation status on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in stage IV non-small-cell lung cancer (NSCLC)
    Sanchez, J., Sr.
    Molina, M.
    Moran, T.
    Stahel, R. A.
    Ramirez, J.
    Salazar, F.
    Garrido Lopez, P.
    Bertran-Alamillo, J.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] MCPH1 (BRIT1) AND OUTCOME TO ERLOTINIB IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Garcia-Campelo, R.
    Sanchez, J. J.
    Costa, C.
    Queralt, C.
    De Aguirre, I.
    Molina, M. A.
    Majem, M.
    Cros, S.
    Capdevila, L.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 533 - 533
  • [27] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] FREQUENCY OF EGFR MUTATIONS IN NON-SMALL-CELL LUNG CANCER (NSCLC) FROM GREEK PATIENTS
    Papadopoulou, E.
    Murray, S.
    Efstathiadou, C.
    Nasioulas, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S35 - S36
  • [29] 14-3-3σ Methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival:: The Spanish Lung Cancer Group
    Ramirez, JL
    Rosell, R
    Taron, M
    Sanchez-Ronco, M
    Alberola, V
    Peñas, RD
    Sanchez, JM
    Moran, T
    Camps, C
    Massuti, B
    Sanchez, JJ
    Salazar, F
    Catot, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9105 - 9112
  • [30] Expression of MET, IGF-IR, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations
    Costa, C.
    Gimenez Capitan, A.
    Mayo, C.
    Simonetti, S.
    Majem, M.
    Isla, D.
    Benlloch, S.
    Taron, M.
    Sanchez, J.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345